All In Biotech

Drug Trial Radar · NCT05549947

Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacokinetics of SHR-1819 Injection in Adults With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 158 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

158

Actual

Start

Oct 8, 2022

Primary completion

Sep 15, 2023

Study completion Nov 23, 2023

Sponsor

Sponsor type
Industry
First posted
Sep 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis.

Conditions

  • Moderate to Severe Atopic Dermatitis

Interventions

  • SHR-1819Drug

    Treatment group A: SHR-1819 injection dose 1; Treatment group B: SHR-1819 injection dose 2; Treatment group C:SHR-1819 injection dose 3.

  • PlaceboDrug

    Treatment group D: placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. At 16 weeks, the proportion of subjects who achieved eczema area and severity index (EASI) -75 (EASI score decreased ≥ 75% from baseline)Time frame: Up to 16 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Sub-Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.